Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 2026
26.6.2026 10:28:00 CEST | Business Wire | Press Release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award.
The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide.
This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational discipline and financial rigour that underpin sustainable growth. With a growing geographic footprint, focused investments in innovation and industrial capabilities, and a culture built on scientific excellence and patient-centricity, Stallergenes Greer is committed to improving quality of life for people with allergies worldwide. The Best Managed Companies evaluation highlighted Stallergenes Greer strategic clarity, agile leadership, operational resilience, innovation-driven growth, and strong governance, which together create sustainable long-term value for all stakeholders.
“Being recognised as one of Switzerland's Best Managed Companies is a distinction that belongs first and foremost to our people who translate our strategy into action every day, live our values and embrace the culture of rigour and agility that has defined our company for more than 120 years. Disciplined management and an unwavering commitment to advancing allergy care are the foundations of our company. This award motivates us to keep raising the bar for patients and healthcare professionals, while also further enabling us to attract the best talents worldwide,” stated Dr Andreas Amrein, Chairman of the board and CEO, Stallergenes Greer.
The Best Managed Companies programme is an initiative of Deloitte Private, in collaboration with SIX Swiss Exchange, Zurich Chamber of Commerce, EFG Private Banking and WillisHenry.
“The companies that won the Best Managed Companies Award have every right to be proud: they have undergone an intensive evaluation process and have impressively demonstrated that they manage their company in an exemplary manner in each of the four key entrepreneurial areas, strategy, productivity & innovation, culture & commitment, and governance & finance”, emphasises Andreas Bodenmann, Best Managed Companies Programme Leader at Deloitte Switzerland.
About Switzerland’s Best Managed Companies
Switzerland’s Best Managed Companies programme is an awards programme recognising privately held companies for their organisational success and achievement. The programme provides a distinct framework for management teams to challenge themselves and benchmark against some of the best private companies in the world.
The Best Managed Companies programme was established in 1993 in Canada and has become the most significant business award of its kind. The programme is active in 50+ countries across the Americas, Europe and Australasia.
For more information on the awards programme, visit: www.bestmanagedcompanies.ch
About Stallergenes Greer
Headquartered in Baar (Switzerland), Stallergenes Greer is a leading global biopharmaceutical company specialising in allergen immunotherapy for human and veterinary use. Its activities span the full value chain, from product development and commercialisation to allergy diagnosis and treatment. Backed by more than 120 years of expertise and innovation, the company’s products reach patients in 46 countries worldwide.
For more information, visit: www.stallergenesgreer.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260626690093/en/
Contacts
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press Release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press Release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press Release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press Release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press Release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom